Akiyama Takuya, Fujishiro Takashi, Sugimoto Koichiro, Sakata Rei, Saito Hitomi, Honjo Megumi, Aihara Makoto
Department of Ophthalmology, Asahi General Hospital, Asahi, Japan.
Department of Ophthalmology, Graduate School of Medicine, The University of Tokyo Hospital, 7-3-1, Bunkyo-ku, Tokyo, Japan.
Jpn J Ophthalmol. 2022 Nov;66(6):549-558. doi: 10.1007/s10384-022-00938-9. Epub 2022 Aug 17.
To evaluate the effectiveness of MicroPulse transscleral laser therapy (MP-TLT) using both the original and revised MicroPulse P3 delivery probes in patients with refractory glaucoma.
Retrospective study METHODS: We analyzed the data of patients with refractory glaucoma who underwent MP-TLT with the original and with the revised MicroPulse P3 Delivery Device from January 2018 to December 2020 at the University of Tokyo Hospital and who were followed up for 3 months. Patients' demographics, preoperative and postoperative intraocular pressure (IOP), medication scores, best-corrected visual acuity (BCVA), and complications were analyzed.
This study enrolled 40 patients in both probe groups. At baseline, the mean IOP was 31.1 mmHg in the original group and 29.2 mmHg in the revised group, and it decreased to 22.6 mmHg and 21.6 mmHg after 3 months, respectively (paired t-test p=0.001, 0.001). No significant difference was noted between the number of medications and BCVA at baseline and 3 months in either probe group (paired t-test, p>0.05). Nor were any serious complications observed.
MP-TLT using the revised MicroPulse P3 Delivery Device for the treatment of refractory glaucoma was effective in reducing IOP across glaucoma types with an excellent safety profile and was well-tolerated by the patients.
评估使用原装和改良型微脉冲P3发射探头的微脉冲经巩膜激光疗法（MP-TLT）治疗难治性青光眼的有效性。
回顾性研究
我们分析了2018年1月至2020年12月在东京大学医院接受原装和改良型微脉冲P3发射装置MP-TLT治疗且随访3个月的难治性青光眼患者的数据。分析了患者的人口统计学资料、术前和术后眼压（IOP）、用药评分、最佳矫正视力（BCVA）以及并发症情况。
两个探头组各纳入40例患者。基线时，原装组平均眼压为31.1 mmHg，改良组为29.2 mmHg，3个月后分别降至22.6 mmHg和21.6 mmHg（配对t检验p = 0.001，0.001）。两个探头组在基线和3个月时的用药数量和BCVA均无显著差异（配对t检验，p>0.05）。也未观察到任何严重并发症。
使用改良型微脉冲P3发射装置的MP-TLT治疗难治性青光眼可有效降低各类青光眼的眼压，安全性良好，患者耐受性佳。
